Merck snares $269M in U.S. funding to prep manufacturing for Johnson & Johnson's COVID-19 vaccine

SourceFierce Pharma
Date Published03/03/2021
Author NameFraiser Kansteiner
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
Capital investment ($):268.8
If relevant, work nearshored to:-
Product(s) reshoredcovid-19 vaccine
What domestic positive factors made reshoring more attractive?Government Incentives, Under-utilized capacity, essential product, Biden
Government Incentive dollar amount:BARDA $268.8 million
Find Reshoring Articles